Recent exceptional positive changes in fundamentals have benefitted Pediatrix Medical Group Inc (NYSE: MD): the consensus estimate for December, 2025 increased significantly, the stock’s power rating rose above 70, the consensus estimate for December, 2026 increased significantly, and significant quarterly earnings acceleration occurred.
In light of these very positive signals we are reviewing our current Overall Rating of C. We would view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
Pediatrix Medical Group has a current Value Trend Rating of C (High Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing inconsistent signals. Pediatrix Medical Group has a neutral Appreciation Score of 41 but a good Power Rating of 70, with the High Neutral Value Trend Rating the result.
Recent Price Action
Pediatrix Medical Group Inc (NYSE: MD) stock closed at $16.64 on 9/12/25 after a decline of -2.2%. However, this decline was accompanied by below average trading volume at 69% of normal. The stock has declined -2.2% during the last week but has been strong relative to the market over the last nine months.
Be the first to comment